Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

418P - A PET/CT image-based deep learning approach for precise survival prognosis and clinical management of treatments in patients with esophageal carcinoma

Date

27 Jun 2024

Session

Poster Display session

Presenters

Jian-Hua Liu

Citation

Annals of Oncology (2024) 35 (suppl_1): S162-S204. 10.1016/annonc/annonc1482

Authors

J. Liu1, J. Song2

Author affiliations

  • 1 Guangdong General Hospital, Guangzhou/CN
  • 2 The First Affiliated Hospital of China Medical University, Shenyang/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 418P

Background

The clinical decision-making regarding carrying out surgery alone (SA) or surgery followed by postoperative adjuvant chemotherapy (SPOCT) in esophageal squamous cell carcinoma (ESCC) remains controversial. This study aimed at proposing a pre-therapy PET/CT image-based deep learning approach to improve the survival benefit and clinical management of patients with ESCC.

Methods

This retrospective multicenter study included 837 patients with ESCC from three institutions. Prognostic biomarkers integrating six networks were developed to build an ESCC prognosis (ESCCPro) model and predict the survival probability of patients with ESCC treated with SA and SPOCT. Patients who did not undergo surgical resection were in a control group. Overall survival (OS), disease-free survival, and progression-free survival were the end-point events. Seven clinicians with varying experience evaluated how ESCCPro performed in assisting clinical decision making.

Results

For SA patients, ESCCPro yielded a C-index of 0.705 for predicting OS in the test dataset. No significant differences in survival were found between SA patients with predicted poor outcomes and the control cohort (P > 0.05). For SPOCT patients, ESCCPro yielded a C-index of 0.695 for predicting OS in the test dataset. The clinical implementation of ESCCPro improved the median OS by 8 months and the 2-year OS rate by 12.0% in SA patients. It also improved the median OS by 15 months and the 3-year OS by 24.0% in SPOCT patients, and significantly improved prognosis accuracy, certainty, and the efficiency of clinical experts.

Conclusions

ESCCPro improved the survival benefit of patients with ESCC and aided in the clinical decision-making among the two treatment approaches.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.